Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins  by Bogerd, Hal P et al.
Cell, Vol. 82, 485-494, August 11, 1995, Copyright © 1995 by Cell Press 
Identification of a Novel Cellular Cofactor 
for the Rev/Rex Class 
of Retroviral Regulatory Proteins 
Hal P. Bogerd, Robert A. Fridell, Steven Madore,* 
and Bryan R. Cullen 
Howard Hughes Medical Institute 
and Department of Genetics 
Duke University Medical Center 
Durham, North Carolina 27710 
Summary 
HIV-1 Rev is the prototype of a class of retroviral regu- 
latory proteins that induce the sequence-specific nu- 
clear export of target RNAs. This function requires the 
Rev activation domain, which is believed to bind an es- 
sential cellular cofactor. We report the identification 
of a novel human gene product that binds to not only 
the HIV-1 Rev activation domain in vitro and in vivo 
but also to functionally equivalent domains in other 
Rev and Rex proteins. The Rev/Rex activation domain- 
binding (Rab) protein occupies a binding site on HIV-1 
Rev that precisely matches that predicted by genetic 
analysis. Rab binds the Rev activation domain when 
Rev is assembled onto its RNA target and can signifi- 
cantly enhance Rev activity when overexpressed. We 
conclude that Rab is the predicted activation domain- 
specific cofactor for the Rev/Rex class of RNA export 
factors. 
Introduction 
The human immunodeficiency virus type 1 (HIV-1) Rev 
protein is required for the nucleocytoplasmic transport, 
and hence translation, of a class of incompletely spliced 
HIV-1 mRNAs that encode the viral structural proteins (re- 
viewed by Cullen, 1992). In the absence of Rev, these late 
viral RNAs remain sequestered in the nucleus until they 
are either spliced or degraded (Emerman et al., 1989; 
Felber et al., 1989; Malim et al., 1989b). Rev function is 
therefore essential for the production of progeny virions 
by HIV-1 infected cells (Feinberg et al., 1986; Sodroski et 
al., 1986). 
Rev-mediated nuclear RNA export requires the direct 
interaction of Rev with a cis-acting, -234 nt RNA stem- 
loop structure termed the Rev response element (RRE) 
(Daly et al., 1989; Malim et al., 1989b, 1990). It has been 
proposed that Rev first binds to a high affinity site within 
the RRE as a monomer (Bartel et al., 1991; Tiley et al., 
1992b). Subsequently, additional Rev monomers assem- 
ble onto the RRE in an ordered process mediated by both 
protein-protein and protein-RNA interactions. This multi- 
merization event is critical for Rev function via the RRE 
(Malim and Cullen, 1991; Iwai et al., 1992; McDonald et 
al., 1992). 
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Mutational analysis of the 116 amino acid Rev transacti- 
vator has identified two functional domains (Figure 1). A 
more amino-terminal basic domain acts as both a nuclear/ 
nucleolar localization signal and as a sequence-specific 
RNA-binding domain (Malim et al., 1989a; Cochrane et 
al., 1990; Kjems et al., 1992). This domain is flanked by 
sequences that are essential for efficient Rev multimeriza- 
tion (Malim and Cullen, 1991). Toward the carboxyl ter- 
minus of Rev lies a short ( -  10 amino acid) leucine-rich 
sequence, termed the Rev activation domain, that is dis- 
pensable for RRE binding but nevertheless essential for 
Rev function (Figure 1) (Malim et al., 1989a, 1991; Ven- 
katesh and Chinnadurai, 1990). At least two lines of evi- 
dence suggest that the activation domain represents a 
binding site for an essential cellular Rev cofactor. Most 
importantly, this short sequence element is the only part 
of Rev whose integrity is essential for Rev function via a 
heterologous RNA target site (McDonald et al., 1992). 
Thus, it has been demonstrated that a fusion protein con- 
sisting of Rev linked to the MS2 bacteriophage coat protein 
can induce the nuclear export of an RNA containing multi- 
ple copies of the MS2 coat protein RNA-binding site. Muta- 
tions known to block the activity of the Rev RNA-binding 
or multimerization sequence (or both) prevent he function 
of this fusion protein via the RRE yet fail to inhibit function 
via the MS2 RNA operator. In contrast, mutation of the 
Rev activation domain abrogates function via either RNA 
target (McDonald et al., 1992). These data therefore imply 
that the primary role of the Rev RNA-binding/multimeriza- 
tion domain is to facilitate the assembly of a Rev-RRE 
ribonucleoprotein complex that then recruits the appro- 
priate cellular cofactor to the Rev activation motif. 
A second line of evidence indicating that the activation 
domain is a Rev cofactor-binding domain derives from the 
observation that mutant Rev proteins containing an intact 
RNA-binding/multimerization domain, but lacking a func- 
tional activation domain, exhibit a potent dominant nega- 
tive phenotype in vivo (Malim et al., 1989a, 1991;.Ven- 
katesh and Chinnadurai, 1990). It has been proposed that 
these Rev mutants participate with wild-type Rev in the 
formation of the Rev-RRE ribonucleoprotein complex but 
then block the function of the wild-type Rev by interfering 
with the cooperative recruitment of a cellular cofactor. The 
observation that Rev is functional in cells derived from a 
wide range of eukaryotes, including primates, mice, birds, 
frogs, fruit flies, and even yeast, implies that this unidenti- 
fied cellular cofactor must have been evolutionarily con- 
served (Ivey-Hoyle and Rosenberg, 1990; Malim et al., 
1991; Fischer et al., 1994; Stutz and Rosbash, 1994). 
While HIV-1 Rev is the most intensely studied retroviral 
RNA transport factor, other members of the lentivirinae 
also encode Rev proteins, while the effectively unrelated 
T cell leukemia viruses, including human T cell leukemia 
virus type I (HTLV-I), encode an equivalent regulatory pro- 
tein termed Rex (Cullen, 1992). For many of these other 
Rev and Rex proteins, it has proven possible to muta- 
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Figure 1. Primary Sequence of the Minimal Activation Domains of 
Selected Rev and Rex Proteins 
HIV-1 Rev contains an amino-terminal sequence that mediates RNA 
binding and Rev multimerization and a carboxy-terminal ctivation 
domain that is required for the recruitment of an essential cellular 
cofactor. The HIV-1 Rev activation domain is -10 amino acids in 
length and includes four important leucine residues. Rev proteins en- 
coded by other primate and ovine/caprine lentivirusee are similar to 
HIV-1 Rev in both their domain organization and their activation do- 
main sequence. In contrast, while both EIAV Rev and HTLV-I Rex also 
contain defined domains that can functionally replace the activation 
domain of HIV-1 Rev, these display little sequence similarity. 
tionally define short protein motifs that can functionally 
substitute for the activation domain of HIV-1 Rev (Hope 
et al., 1991; Tiley et al., 1991). In the case of the other 
primate lentiviruses, as well as the more divergent ovine/ 
caprine lentiviruses visna-maedi virus (VMV) and caprine 
arthritis encephelitis virus, the Rev activation domain has 
been found to be similar in size and composition to that 
present in H IV-1 Rev (Malim et al., 1991 ; Tiley et al., 1991) 
(Figure 1). However, both the Rev protein encoded by the 
lentivirus equine infectious anemia virus (EIAV) and the 
Rex protein of HTLV-I shares no significant sequence ho- 
mology with HIV-1 Rev and contains larger, divergent acti- 
vation domains (Hope et al., 1991; Weichselbraun et al., 
1992; Fridell et al., 1993; Mancuso et al., 1994). In the 
case of HTLV-I Rex, this -15  amino acid sequence can 
be at least partially aligned with the relevant HIV-1 Rev 
sequence (Figure 1). In contrast, the - 18 amino acid acti- 
vation domain of EIAV Rev displays no evident sequence 
similarity to the - 10 amino acid HIV-1 Rev activation mo- 
tif, even though it can effectively substitute for the latter 
in mediating HIV-1 Rev function. Nevertheless, the func- 
tional equivalence of each of these protein sequences in 
vivo strongly suggests that they are each likely to interact 
with the same cellular cofactor. Here, we report the identifi- 
cation and initial characterization of this shared activation 
domain-specif ic Rev/Rex cofactor. 
Results 
Using the yeast two-hybrid protein interaction trap (Fields 
and Song, 1989; Fridell et al., 1995), we sought to identify 
a human cDNA that encoded a protein able to interact 
not only with HIV-1 Rev but also with HTLV-I Rex in an 
activation domain-dependent manner. The screened li- 
brary consisted of the VP16 transcription activation do- 
main fused to cDNA sequences derived from the human 
CEM Tcell line. This screen led to the identification of three 
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Rev Mutant Rev Activity Rab Binding 
WT ++ 1.00 
M10 - <0.01 
M15 ++ 0.57 
M16 ++ 1.06 
M17 ++ 0.25 
M18 + 0.10 
M19 ++ 1.79 
M20 + 0.16 
M21 - <0.01 
M22 - <0.01 
M23 ++ 3.63 
M24 + 0.12 
M25 ++ 1.87 
M27 - <0.01 
M29 - <0.01 
Figure 2. The Ability of Rev Activation Domain Mutants to Function 
In Vivo Closely Correlates with Their Ability to Bind Rab 
A set of scanning missense mutations across the HIV-1 Rev activation 
domain has been previously described (Malim et al., 1991). In brief, 
all two amino acid mutations (M10, M15-M18, and M20-M22) have 
aspartic acid and leucine substituted in place of the wild-type se- 
quence. Single amino acid mutations feature a substituted aspartic 
acid (M19) or alanine (M27 and M29) residue, while three amino acid 
mutations contain the inserted sequence glutamic acid-aspartic acid- 
leucine (M23 and M25) or lysine-aspartic acid-leucine (M24). The in 
vivo biological activity of these Rev mutants has been reported (Malim 
et al., 1991) and is as follows: double plus, >50% of wild-type Rev 
function; plus, ~<50% of wild-type; and minus, negative phenotype. 
Each Rev mutant was expressed in the yeast indicator strain GGY1 :: 
171 as a GAL4 fusion protein, and the level of ~-gal activity induced 
by coexpression of the VP16-Rab fusion was determined. This mea- 
sure of the ability of each Rev mutant o bind Rab is expressed relative 
to the wild-type GAL4-Rev fusion protein, which is set at 1.0. 
clones that encoded VP16 fusion proteins that specifically 
interacted with the GAL4-Rev bait protein and 10 clones 
expressing VP16 fusion proteins that specifically bound 
GAL4-Rex. None of the three Rev-specific clones were 
able to interact with GAL4-Rex, while only one of the 10 
Rex-specific clones could bind to GAL4-Rev. Further ex- 
periments demonstrated that this interaction was entirely 
blocked by the introduction of point mutations into the acti- 
vation domains of either Rev or Rex (data not shown). 
Based on this initial observation, we designated this hu- 
man protein as the Rev/Rex activation domain-binding 
protein (Rab). 
Rab Binds the Rev Activation Domain Specifically 
To define more fully the protein sequence specificity of 
the interaction of Rev with Rab, we took advantage of a 
previously described (Malim et al., 1991) set of scanning 
missense mutations that precisely map the HIV-1 Rev acti- 
vation domain (Figure 2). These mutations each affect 
from one to three amino acids either within or adjacent to 
the activation domain and give rise to wild-type, intermedi- 
ate, or negative phenotypes when assayed for Rev func- 
tion in mammalian cells. This complete set of Rev mutants 
was cloned into a yeast GAL4 fusion protein expression 
plasmid, and each mutant was individually tested for its 
ability to interact with the VP16-Rab fusion protein in the 
yeast cell nucleus, as assessed by the level of activation 
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Figure 3. Predicted Primary Sequence of the Human Rab Protein 
The rab cDNA contains a single long ORF that is here translated from 
the first in-frame initiation codon. In vitro translation of this sequence 
gives rise to a protein that is the same size as the Rab protein detected 
in vivo (see below). Phenylalanine residues, including the dipeptide 
motif FG, as well as runs of serines are indicated. 
of an integrated lacZ indicator gene. Each of these mutant 
GAL4-Rev  fusion proteins was equivalently stable in 
yeast, as measured by Western blot analysis (data not 
shown). 
As shown in Figure 2, five Rev mutants that entirely lack 
effector domain function, including two mutants (M27 and 
M29) that bear only single amino acid changes in Rev, 
all proved entirely unable to interact with the Rab fusion 
protein. In contrast, all of the Rev mutants previously 
shown (Malim et al., 1991) to exhibit substantially wild-type 
Rev act iv ity in v ivo also induced substant ia l  levels of 
I~-galactosidase (~-gal) activity, ranging from a minimum 
of one quarter to a maximum of approximately three times 
the level seen with wild-type Rev. Strikingly, the three Rev 
mutants (M18, M20, and M24) previously shown (Malim 
et al., 1991) to exhibit only partial (~<50%) Rev function in 
vivo also proved to be significantly attenuated in their abil- 
ity to interact with Rab (~<16% of wild type). It is therefore 
apparent that there is a very close concordance between 
the ability of Rev activation domain mutants to function 
in the recruitment of the Rev cofactor in mammalian cells 
and the ability of these same Rev activation domain mu- 
tants to interact with the Rab protein in the yeast cell nu- 
cleus. 
Sequence of the tab Gene Product 
The rab cDNA clone contains a 2584 bp insert f lanked 3' 
by a stretch of A residues, consistent with priming at the 
mRNA poly(A) tail. Starting at the first in-frame methionine 
residue, this cDNA contains an open reading frame (ORF) 
of 562 amino acids that would be predicted to encode 
a protein of -58  kDa (Figure 3). Computer analysis of 
available sequence databases failed to identify any pro- 
teins displaying significant homology to the predicted Rab 
ORF. Similarly, we were also unable to identify any nucleic 
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Figure 4. Analysis of tab RNA and Protein Expression 
(A) Northern blot analysis of poly(A) + RNA from the human cell lines 
CEM and HeLa. The relative mobility of marker RNA species is shown 
at the left of the blot while the extrapolated size of the hybridizing RNA 
species is given at right in kilobases. 
(8) Western blot analysis of Rab protein expression. Proteins extracted 
from cells obtained from the indicated species were separated by 12% 
SDS-PAGE, transferred to nitrocellulose, and then subjected to West- 
ern blot analysis using an affinity-purified rabbit anti-Rab antiserum. 
The blot shown on the right was performed in the presence of soluble 
Rab protein to assess signal specificity. 
(C) Immunofluorescence analysis of CV1 cells probedwith the rabbit 
anti-Rab antiserum followed by rhodamine-conjugated goat anti-rabbit 
antiserum. 
(D) Interaction of Rab with HIV-1 Rev in vitro. Equal levels ofa radioac- 
tively labeled preparation of the - 60 kDa Rab protein were loaded 
onto columns containing GST, GST fused to HIV-1 Rev (GST-Rev), 
or GST fused to the M10 Rev activation domain mutant (GST-M10). 
After extensive washing, bound proteins were eluted from the columns 
and subjected to 1L~o/0 SDS-PAGE. The Rab protein did not bind to 
the GST or GST-M10 columns but was specifically retained by the 
GST-Rev column. The relative mobility ofmarker proteins of the indi- 
cated size (in kilodaltons) is given at the left of (B) and (D). 
acid sequences that displayed significant homology to rab 
except for two short, unidentified expressed sequence 
tags. rab is therefore a novel human gene. An unusual 
aspect of the Rab protein sequence is the high concentra- 
tion of phenylalanine residues, including 10 in the form of 
the dipeptide motif FG, as well as several runs of serine 
residues, found concentrated toward the carboxyl termi- 
nus of Rab. The potential significance of these is dis- 
cussed below. 
Analysis of tab mRNA and Protein Expression 
The tab cDNA insert was used to probe a Northern blot 
of mRNA derived from the human T cell line CEM (the 
origin of the cDNA clone) and the human cell line HeLa. 
In both cases, a prominent band of - 2.8 kb was observed 
(Figure 4A). Both cell lines also expressed a hybridizing 
band of - 4.6 kb, although this was faint in the CEM cells. 
Similarly, Northern blot analysis of rab mRNA expression 
in a range of human tissues also identified a major 2.8 kb 
and a minor 4.6 kb tab transcript in all tissues examined 
Cell 
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(data not shown). Based on this analysis, it therefore ap- 
peared that this cloned rab cDNA is close to the full length 
of the major species of rab mRNA expressed in human 
cell lines and tissues. 
An interesting characteristic of both Rev and Rex is that 
these retroviral regulatory proteins are functional in a wide 
range of animal cells (Ivey-Hoyle and Rosenberg, 1990; 
Malim et al., 1991; Fischer et al., 1994). Therefore, it is 
predicted that the cellular cofactor for Rev and Rex should 
be conserved across species boundaries. To test this hy- 
pothesis, we performed a Western blot analysis on cellular 
protein extracts of mammalian, avian, amphibian, and in- 
vertebrate origin using an affinity-purified polyclonal rabbit 
anti-Rab antiserum (Figure 4B). In humans, this procedure 
identified a predominant band of -60  kDa (Figure 4B, 
lane 1), and bands of identical mobility were also detected 
in cellular extracts of mouse, quail, and frog origin (lanes 
2-4). In the fruit fly, a slightly smaller cross-reactive band 
was observed (Figure 4B, lane 5). These bands all repre- 
sented authentic Rab-related proteins, in that reactivity 
could be specifically blocked by addition of a purified, solu- 
ble maltose-binding protein (MBP)-Rab fusion protein to 
the Western blot during the antibody-binding step (Figure 
4B, lanes 6-8). 
An indirect immunofluorescence analysis of the localiza- 
tion of endogenous Rab protein in the primate cell line 
CV1, using the Rab-specific rabbit antiserum, is shown in 
Figure 4C. This experiment revealed that Rab is concen- 
trated in the nucleus and nucleolus of these cells in a 
pattern that is similar to that observed previously with 
HIV-1 Rev and HTLV-I Rex (Siomi et al., 1988; Felber et al., 
1989). No specific signal was detected when a matched 
preimmune rabbit serum was used (data not shown). While 
Western blot analysis of nuclear and cytoplasmic protein 
fractions derived from HeLa cells further confirmed the 
nuclear concentration of Rab, this latter analysis also de- 
tected significant levels of cytoplasmic Rab protein (data 
not shown). It therefore appears that Rab is primarily, but 
not exclusively, nuclear in localization. 
Although we have been unable to express the full-length 
Rab protein in a soluble form in bacteria, we are able to 
express limited amounts of soluble Rab protein in vitro by 
translation of rab mRNA in a rabbit reticulocyte lysate. 
Translation of the Rab ORF indicated in Figure 3 gave 
rise to a protein that migrated on polyacrylamide gels with 
the same relative molecular mass as the major Rab anti- 
body-reactive species detected in human cells in vivo (Fig- 
ure 4). Therefore, the Rab ORF shown in Figure 3 is full 
length. 
We next used ~sS-labeled full-length Rab protein gener- 
ated by in vitro translation to ask whether Rab would bind 
the Rev activation domain specifically in vitro (Figure 4D). 
For this purpose, we loaded equal levels of the 3~S-labeled 
Rab protein onto columns containing either glutathione 
S-transferase (GST) or fusion proteins consisting of GST 
linked to Rev (GST-Rev) or the M10 activation domain 
Rev mutant (GST-M10), conjugated to agarose beads. 
After extensive washing, remaining bound proteins were 
eluted and subjected to SDS-polyacrylamide gel electro- 
phoresis (SDS-PAGE). As shown in Figure 4D, the labeled 
Rab protein was not retained by the GST or GST-M10 
columns but did bind to the GST-Rev column. These data 
therefore demonstrate that the specific interaction of Rab 
with the Rev activation domain can be recapitulated in vitro 
and also strongly suggest that this interaction is direct. 
Rab Binds the Activation Domains of Diverse Rev 
and Rex Proteins In Vivo 
We next wished to ask whether the interaction of Rab 
with Rev could be demonstrated in mammalian cells and 
whether other Rev and Rex proteins, particularly including 
the highly divergent EIAV Rev (see Figure 1), would also 
bind to Rab specifically. To address these issues, we per- 
formed a mammalian version of the two-hybrid analysis 
using transient transfection of the primate cell line COS 
(Figure 5). The pG5B-CAT indicator plasmid used in this 
analysis contains five GAL4 sites located 5' to a minimal 
promoter element directing expression of the chloram- 
phenicol acetyl transferase (CAT) gene (Bogerd and 
Greene, 1993). In this assay, the identities of the bait-and- 
prey proteins were reversed such that the Rab protein was 
now expressed as a GAL4-Rab fusion while the full-length 
HIV-1, VMV, and EIAV Rev proteins and the HTLV-I Rex 
protein were each expressed as VP16 fusion proteins. For 
each Rev and Rex protein, plasmids bearing a deleterious 
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Figure 5. Rab Interacts with the Activation Domains of Multiple Rev 
and Rex Proteins in the Mammalian Nucleus 
The Rab protein was expressed as a GAL4 fusion and the indicated 
retroviral regulatory proteins as VP16 fusions. The level of CAT en- 
zyme activity detected in a COS cell culture transfected with pBC12- 
GAL4-Rab and the pG5B-CAT indicator plasmid was set at 1.0. Levels 
of CAT expression observed when COS cultures were additionally 
cotransfected with the indicated VP16 fusion protein expression plas- 
mids are given as multiples of this value. VP16 fusion proteins con- 
taining the wild-type forms of HIV-1, VMV and EIAV Rev, or HTLV-I 
Rex protein were each able to assemble onto the GAL4-Rab protein 
bound to the pG5B-CAT-indicator plasmid, resulting in a 20- to 40-fotd 
increase in CAT enzyme activity. In contrast, mutation of the activation 
domains present in each of these Rev or Rex proteins (indicated by 
M10 or M32 for HIV-1 Rev or AAD for the other proteins) effectively 
blocked this in vivo interaction. Data shown are representative of multi- 
ple independent transfection experiments that were each internally 
controlled by cotransfection of a 13-gal expression plasmid, (See Experi- 
mental Procedures for description of the mutants used.) 
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Figure 6. The Rab Protein Binds the Rev-FIRE Ribonucleoprotein 
Complex In Vivo 
(A) Schematic representation of an in vivo monohybrid assay for Rab 
binding to the Rev-RRE ribonucleoprotein complex. See text for dis- 
cussion of the experimental strategy. 
(B) Activation of the SLIIB-CAT indicator construct in HeLa cells upon 
cotransfection of the indicated expression plasmids. Only the combina- 
tion of both the Tat-Rab fusion protein and the wild-type Rev protein 
results in activation of the HIV-1 LTR-linked CAT indicator gene. Intro- 
duction of the M10 or M32 mutation into the HIV-1 Rev activation 
domain blocks the in vivo interaction of Rab with the RNA-bound Rev 
protein. 
missense mutation in the mutationally defined activation 
domain were also generated (Figure 5). All VP16 fusion 
proteins were expressed at comparable levels after trans- 
fection into COS cells (data not shown). 
Transient transfection of COS cell cultures with the 
pG5B-CAT indicator plasmid, along with the pBC12-GAL4- 
Rab expression plasmid, gave only a low level of CAT 
enzyme activity. While this level was not significantly en- 
hanced by coexpression of a Tat-VP16 fusion protein, 
a similar Rev-VP16 fusion protein produced a marked 
( -  18-fotd) induction in the level of CAT activity (Figure 5). 
In contrast, two Rev-VP16 fusion proteins bearing either 
the M10 or the M32 missense mutation of the Rev activa- 
tion domain (Malim et al., 1991) each failed to enhance 
expression of the CAT indicator gene. 
Similar evidence for an in vivo interaction with Rab was 
also obtained using VP16 fusion proteins containing either 
the HTLV-I Rex protein or the VMV Rev or more highly 
divergent EIAV Rev protein (Figure 5). In each case, intro- 
duction of a m issense mutation (AAD) known to block acti- 
vation domain function markedly inhibited the in vivo inter- 
action with GAL4-Rab. We therefore conclude that Rab 
can interact with a range of highly divergent Rev and Rex 
proteins in the mammalian cell nucleus and that the integ- 
rity of the mutationally defined activation motifs is, in each 
case, critical to this interaction. It should be noted that the 
endogenously expressed Rab protein (see Figure 4) would 
be predicted to act as an efficient competitive inhibitor 
of the in vivo interaction between GAL4-Rab and these 
various Rev or Rex fusion proteins. It is therefore likely 
that the data presented in Figure 5 significantly underesti- 
mate the efficiency of this in vivo interaction. 
Rab Binds to the Rev Activation Domain When Rev 
Is Bound to the RRE 
An important predicted property of the cellular cofactor 
for HIV-1 Rev is that it should be able to interact efficiently 
with the Rev activation domain when Rev is assembled 
onto the RRE RNA target. To test whether Rab satisfied 
this prediction, we devised an in vivo genetic assay that 
uses the HIV-1 tat RNA sequence-specific transcriptional 
activator to provide an indirect measure of the assembly 
of a protein complex onto an RNA target sequence (Figure 
6A). Normally, Tat activates gene expression from the 
HIV-1 long terminal repeat (LTR) after binding a cis-acting 
RNA target sequence, termed TAR, that forms the first 59 
nt of all HIV-1 transcripts (Cullen, 1992). We have pre- 
viously shown that if the TAR RNA stem-loop is replaced 
with the RRE-derived stem-loop lib (SLIIB) minimal RNA 
target sequence for HIV-1 Rev, then trans-activation of the 
HIV-1 LTR can only be observed if Tat is fused to an HtV-1 
Rev protein bearing an intact RNA-binding domain (Tiley 
et al., 1992a). 
The assay delineated in Figure 6A takes this approach 
one step further. Here, the TAR element is again replaced 
by RRE SLIIB in an indicator construct in which the HIV-1 
LTR is linked to CAT (pSLIIB-CAT). However, in this case, 
Rev is expressed in its wild-type form while Tat is ex- 
pressed as a Rab fusion protein. Only if Rab can induce 
the efficient recruitment of this Tat-Rab fusion protein to 
the RRE-bound Rev protein will Tat be brought o the HIV-1 ' 
LTR promoter element and, hence, be able to activate 
HIV-1 LTR-driven CAT expression (Figure 6A). 
Results obtained using this monohybrid assay on the 
homologous RRE RNA target are presented in Figure 6B. 
As can be readily seen, neither HIV-1 Rev alone nor the 
Tat-Rab fusion protein alone was able to induce a level 
of CAT expression that exceeded the basal level seen 
in HeLa cells transfected with the pSLIIB-CAT indicator 
construct alone. However, the simultaneous expression 
of both Rev and Tat-Rab in the nuclei of these human 
cells induced a readily detectable - 19-fold induction in 
CAT protein expression. Assembly of Rab onto the Rev- 
RRE ribonucleoprotein complex was, as predicted, fuliy 
dependent on the integrity of the Rev activation domain 
as shown by the lack of activity of the Rev M10 and M32 
activation domain mutants in this assay (Figure 6B). Im- 
portantly, these two mutations have no effect on the ability 
of Rev to bind the RRE in vivo (Tiley et al., 1992a). 
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Figure 7, Overexpression of Rab Enhances HIV-1 Rev and HTLV-I 
Rex Function 
COS cell cultures (35 ram) were transfeeted with 100 ng of the Rev- 
defective HIV-1 provirus expression plasmid pHIVARev, together with 
either 50 ng of the HIV-1 Rev expression plasmid pcRev or t00 ng of 
the HTLV-I Rex expression plasmid pcRex, In addition, each culture 
was transfected with 1 p.g of a pBC12-CMV-based plasmid esigned 
to express CAT, 13-gal, or Rab and 20 ng of the indicator plasrnid 
pBC12-CMV-SEAP. At 88 hr after transfection, the supernatant media 
were harvested and levels of secreted p24 capsid protein and SEAP 
determined. While Rab coexpression increased the Rev- or Rex- 
induced production of HIV-1 capsid protein by from 3- to 6-fold, it did 
not significantly affect he low basal expression of p24 (<:20 pg/rnl) 
seen in the absence of Rev and Rex (data not shown). Similarly, Rab 
overexpression also had no significant effect on the production of the 
SEAP internal control (setting mean SEAP activity at 1.0, the observed 
standard eviation was _+ 0.27). Data are representative of three inde- 
pendent experiments. 
Overexpression of Rab Can Enhance Rev and Rex 
Function In Vivo 
The data presented in Figure 6 show that Rab can bind 
to the Rev activation domain when Rev is part of the Rev- 
RRE ribonucleoprotein complex. Therefore, Rab can ef- 
fectively compete with the endogenous Rev cofactor for 
binding to the Rev activation domain. This finding sug- 
gested that an in vivo assay for Rev function performed 
under conditions in which the level of Rev expression was 
suboptimal should be able to uncover a phenotype for Rab 
even in the face of a significant endogenous level of Rab 
expression. In particular, we hypothesized that, if Rab is 
not the authentic Rev cofactor, then overexpression of 
Rab should competitively inhibit Rev function. In contrast, 
if Rab is the authentic Rev cofactor, then overexpression 
of Rab might promote the recruitment of Rab to the RRE 
RNA target by suboptimal evels of Rev protein, leading 
to an increase in Rev activity. Similarly, the HTLV-I Rex 
protein, which can also act via the HIV-1 RRE element 
(Rimsky et al., 1988), might also display enhanced activity 
in the presence of Rab if this protein is indeed the authentic 
Rev/Rex cofactor. 
To test this hypothesis, we first introduced a premature 
termination codon into the rev  gene present in a full-length 
HIV-1 proviral clone. We then transfected the resultant 
HIVARev provirus into COS cells along with different lev- 
els of the HIV-1 Rev expression plasmid pcRev or the 
HTLV-I Rex expression plasmid pcRex (Rimsky et al., 
1988), and we determined the level of each of these plas- 
mids that induced - 10% of the level of p24 capsid protein 
production that was seen with a saturating level of Rev. 
We next transfected COS cells with the HIVARev proviral 
clone, along with this limiting level of either pcRev or 
pcRex, together with an -20-fold molar excess of a 
pBC12-CMV based plasmid (Malim et al., 1991) express- 
ing the full-length Rab protein or expressing either CAT 
or 13-gal as negative control proteins. Based on immuno- 
precipitation analysis, we estimate that cells transfected 
with the Rab expression plasmid express 5- to 10-fold 
higher levels of Rab than normal (data not shown). Trans- 
fection efficiency was monitored by cotransfecting a con- 
stant level of an expression plasmid encoding the secreted 
alkaline phosphatase (SEAP) indicator gene (Berger et al., 
1988). After - 88 hr, the supernatant media were removed 
from the transfected cultures and levels of p24 capsid pro- 
tein and SEAP activity determined. As shown in Figure 7, 
we consistently observed a 3- to 6-fold increase in the 
level of HIV-1 p24 capsid protein secreted by the culture 
overexpressing the Rab protein when compared with the 
cultures expressing either CAT or 13-gal. In contrast, Rab 
overexpression had no significant effect on the level of 
supernatant SEAP activity. These data therefore strongly 
support the hypothesis that Rab is an important human 
cellular cofactor for HIV-1 Rev and HTLV-I Rex. 
Discussion 
The Rev transactivator encoded by HIV-1 is of consider- 
able scientific interest for at least two reasons. First, Rev 
function is critical for the expression of HIV-1 structural 
proteins and, hence, for viral replication in vivo (Feinberg 
et al., 1986; Sodroski et al., 1986). Rev therefore repre- 
sents an attractive target for chemotherapeutic nterven- 
tion in HIV-1 induced disease. Second, HIV-1 Rev is the 
prototype of a novel class of retroviral regulatory proteins 
that act at the level of sequence specific nuclear RNA 
export (Cullen, 1992). Relatively little is known about how 
nucleocytoplasmic RNA transport is regulated in the eu- 
karyotic cell, and a more complete understanding of the 
mechanism of action of Rev may, therefore, also lead to 
important insights into how this fundamental step in the 
expression of the eukaryotic genome is regulated. Im- 
portantly, recent data suggesting that human cells express 
an endogenous activity that can also induce the sequence- 
specific nuclear export of target mRNAs (Huang and 
Liang, 1993; Bray et al., 1994) also suggest that Rev-like 
regulatory proteins, rather than being restr4cted to com- 
plex retroviruses, might also play a critical role in mediat- 
ing the expression of specific cellular genes. 
Previous work on the HIV-1 Rev protein and on the func- 
tionally equivalent Rev and Rex proteins encoded by other 
complex retroviruses led to the mutational definition of 
activation domains that are believed to represent binding 
domains for a cellular cofactor (Figure 1). In the case of 
HIV-1 and other primate and ovine/caprine lentiviruses, 
this activation domain is a discrete ( -10  amino acid) se- 
quence containing four critically spaced leucine or simi- 
larly large hydrophobic amino acids (Figure 1) (Malim et 
al., 1991; Tiley et al., 1991). However, the activation do- 
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mains of the EIAV Rev protein and of the Rex protein of 
HTLV-I, while functionally equivalent to the sequence seen 
in HIV-1 Rev, are nevertheless distinct in terms of not only 
their larger size but also their primary sequence (Hope et 
al., 1991; Weichselbraun et al., 1992; Fridell et al., 1993; 
Mancuso et al., 1994). Together, this divergent set of Rev 
and Rex sequences are nevertheless predicted to bind to 
the same cellular cofactor and thus represent an invalu- 
able tool for the experimental identification and validation 
of this factor. 
In this paper, we report he identification and initial char- 
acterization of a novel human protein that specifically 
binds to each of these Rev and Rex activation domains in 
the mammalian cell nucleus (Figure 5). In fact, this cellular 
protein, which we term Rab, displays precisely the protein 
binding specificity predicted for the authentic cellular co- 
factor for HIV-1 Rev, as demonstrated by the close correla- 
tion between the biological activity and Rab binding ability 
of a large set of HIV-1 Rev activation domain missense 
mutants (Figure 2). We further show that Rab can specifi- 
cally bind to the HIV-1 Rev activation domain in vitro (Fig- 
ure 4D) and that Rab can efficiently assemble onto the 
activation domain when Rev is bound to its homologous 
RRE RNA target in vivo (Figure 6). Most importantly, we 
demonstrate that overexpression of the Rab protein can 
specifically enhance the ability of either HIV-1 Rev or 
HTLV-I Rex to activate HIV-1 structural protein expression 
in transfected cells in culture (Figure 7). Overall, these 
data provide clear evidence in support of the hypothesis 
that Rab is both the cellular target of the various Rev and 
Rex activation domains listed in Figure 1 and an important 
cofactor for HIV-1 Rev and HTLV-I Rex function in vivo. 
Earlier efforts to identify cellular cofactors for HIV-1 Rev 
have led to the identification of two other candidate pro- 
teins. Luo et al. (1994) have demonstrated that the cellular 
protein p32, identified as a factor copurifying with the cellu- 
lar splicing factor ASF/SF2, can bind the arginine-rich 
RNA-binding domain of HIV-1 Rev, and they have also 
argued that overexpression of p32 can enhance Rev func- 
tion. It remains unclear whether the interaction of p32 with 
Rev is truly specific, in that p32 also binds at least equally 
well to the arginine-rich RNA-binding domain of HIV-1 Tat 
(Fridell et al., 1995). In any event, while p32 may well affect 
Rev function, it does not bind to the experimentally defined 
Rev activation domain and therefore cannot be the cellular 
factor that mediates activation domain function. 
In contrast with p32, the other protein that has been 
proposed as a cellular cofactor for HIV-1 Rev, the eukary- 
otic translation initiation factor 5A (eIF-5A), has also been 
suggested to bind to the Rev activation domain, based on 
specific cross-linking of elF-5A to an activation domain 
peptide in vitro (Ruhl et al., 1993). Data have also been 
presented suggesting that microinjection of the elF-5A 
protein into Xenopus oocytes, which do not express de- 
tectable endogenous elF-5A, is required to permit HIV-1 
Rev function in this system (Ruhl et al., 1993). However, 
we have been unable to demonstrate any interaction be- 
tween elF-5A and HIV-1 Rev or HTLV-I Rex using the vari- 
ous genetic assays described in this paper (data not 
shown), while others have recently presented ata arguing 
that Xenopus oocytes are fully permissive for HIV-1 Rev 
function even in the absence of exogenously added elF-5A 
(Fischer et al., 1994). The question of whether elF-5A in- 
deed plays a specific role in mediating HIV-1 Rev function 
therefore remains to be fully addressed. 
While the data presented in this manuscript argue 
strongly for a critical role for Rab in mediating the function 
of retroviral Rev/Rex proteins, they shed relatively little 
light on its normal cellular function. Certainly, the remark- 
able evolutionary conservation of the Rab protein across 
widely divergent eukaryotic species (Figure 4B) is not only 
strongly suggestive of an important biological role but also 
consistent with the lack of species specificity observed 
for HIV-1 Rev function (Ivey-Hoyle and Rosenberg, 1990; 
Malim et al., 1991; Fischer et al., 1994). However, this 
result also makes it difficult o address the normal role of 
Rab by complementation i trans.  
While the primary sequence of the predicted Rab protein 
does not show any significant homology to proteins of 
known function, Rab does contain a remarkably high 43 
phenylalanine residues, including 10 copies of the FG 
amino acid pair, and 16 runs of two or more tandem serine 
residues (Figure 3). These protein sequence elements, 
which are concentrated in the carboxy-terminal half of 
Rab, are also found in several nucleoporin proteins, includ- 
ing particularly the human CAN or nup214 protein, which 
not only contains multiple copies of a highly degenerate 
FG based tetrapeptide repeat element but also numerous 
short serine runs (Kraemer et al., 1994). While the signifi- 
cance of these elements for nucleoporin function remains 
unclear, it is possible that they play a role in mediating 
nucleoporin interactions (Davis, 1995). However, an im- 
munofluorescence analysis of the intracellular localization 
of Rab, while clearly demonstrating that Rab is concen- 
trated in the cell nucleus, did not indicate a localization in 
the nuclear membrane (Figure 4C). While the subcellular 
localization of Rab does not, therefore, support he hypoth- 
esis that Rab is a true nucleoporin, the fact that Rab con- 
tains nucleoporin-like sequence elements does raise the 
intriguing possibility that Rab might interact with certain 
nucleoporins, in a manner analogous to the many estab- 
lished internucleoporin interactions (Davis, 1995), while 
mediating the nuclear export of target RNA species. Alter- 
natively, it is also possible that Rev sequentially interacts 
with Rab and then with authentic nucleoporins, perhaps 
using the same activation domain protein-binding site, as 
part of an ordered pathway leading out of the nucleus to 
the cytoplasm. While both these scenarios must be viewed 
as highly speculative at present, they do provide models 
for the mechanism of action of the Rev/Rex class of RNA 
export factors that are not only interesting but also testable. 
Experimental Procedures 
Yeast Two-Hybrid Interaction Experiments 
The yeast expression plasmid pGAL4-Rev encodes a fusion protein 
consisting of the GAL4 DNA-binding domain linked to the full-length 
HIV-1 Rev protein (Fridell et al., 1995). A series of 14 missense muta- 
tions, in or near the HIV-1 Rev activation domain, were generated in 
the pGAL4-Rev context by replacement of the wild-type rev cDNA 
sequence (XbaI-EcoRI) with polymerase chain reaction (PCR)-gen- 
erated cDNA fragments bearing the previously described mutations 
Cell 
492 
(Malim et al., 1991) listed in Figure 2. The plasmid pGAL4-Rex was 
constructed by substituting amino acids 2-189 of HTLV-I Rex in place 
of the Rev sequence present in pGAL4-Rev. 
The Y190 yeast indicator strain, the preparation of the oligo(dT)- 
primed, pVP16-based CEM cDNA library, and the methodology used 
to screen for interacting proteins have been described previously 
(Harper et al., 1993; Fridell et al., 1995). Following rescue, library 
plasmids expressing relevant VP16 fusion proteins were rescreened 
by transformation into the yeast indicator strain GGY1::171 (Gill and 
Ptashne, 1987) together with the panel of GAL4 fusion protein expres- 
sion plasmids described in Figure 2. After 3 days of selection on culture 
plates, double transformants were transferred to selective liquid me- 
dium. The next day, equal cell equivalents were analyzed for levels 
of ~-gal expression (Fridell et al., 1995). 
When appropriate, molecular clones were sequenced using the di- 
deoxy chain termination method and the Sequenase version 2.0 se- 
quencing kit (United States Biochemical). The rab cDNA insert was 
sequenced by the same method using both dGTP and dlTP. 
RNA and Protein Expression Analysis 
Northern blot analysis of poly(A) + RNA derived from the human cell 
lines CEM and HeLa was performed as previously described (Malim et 
al., 1990) using a random-primed, [a-32P]dCTP-labeled probe prepared 
from an internal 853 bp BamHI-Accl rab cDNA fragment. 
The pGEX-4T plasmid was used to express a fusien protein con- 
sisting of GST linked to amino acids 101-562 of the Rab ORF (Figure 
3) in the BL21 (Ion) strain of Escherichia coll. Expression was induced 
by addition of 0.1 mM IPTG, and the resultant GST-Rab fusion protein 
was extracted, purified, and used to immunize rabbits. A second fusion 
protein, consisting of MBP linked to amino acids 101-326 of Rab, was 
expressed in E. coil using the pMAL-C2 expression plasmid, purified 
using a commercial kit (MBP Fusion and Purification System, New 
England Biolabs) and then coupled to cyanogen bromide-activated 
agarose beads (Pierce). The agarose-coupled MBP-Rab fusion pro- 
tein was used to affinity purify Rab-specific antibodies from the serum 
of the GST-Rab-i njected rabbits using buffers and procedures detailed 
in the Amino Link Immobilization kit (Pierce). The resultant Rab- 
specific rabbit antiserum was concentrated and dialyzed against phos- 
phate-buffered saline (PBS) prior to use. 
The tissue culture cell lines used to make protein extracts were 
HeLa (human), C127 (mouse), QC13 (quail), and Schneider 2 (Dro- 
sophila). Frog protein extracts were prepared from Xenopus oocytes. 
Cells were washed with PBS and then resuspended in 100 ~1 of PBS. 
After addition of 100 I11 of 2 x Laemmli's gel loading buffer containing 
2-mercaptoethanol, the samples were sonicated, boiled, and centri- 
fuged to remove debris. Soluble proteins were separated by 12% 
SDS-PAGE, transferred to a nitrocellulose filter, and then incubated 
with a 1:20,000 dilution of the affinity-purified rabbit Rab antiserum. 
After vigorous washing, bound antibodies were detected using a horse- 
radish peroxidase-conjugated goat anti-rabbit antiserum and en- 
hanced chemiluminescence (Amersham). 
Immunofluorescence analysis was performed essentially as pre- 
viously described (Malim et al., 1989a). CV1 cells were fixed and per- 
meabilized prior to incubation with a 1:1000 dilution of the rabbit anti- 
Rab antiserum. After extensive washing, the fixed cells were incubated 
with a 1:100 dilution of an affinity-purified rhodamine-conjugated goat 
anti-rabbit antiserum (Boehringer Mannheim) and examined using a 
Zeiss Axioskop immunofluorescence microscope. 
GST Affinity Chromatography 
Both the GST-Rev and the GST-M10 fusion proteins, contain the full- 
length Rev ORF, in the former case containing an intact activation 
domain and in the latter the defective M10 mutant form of the activation 
domain (Malim et al., 1989a). In addition, both Rev fusion proteins 
also contain the previously described M6 missense mutation of the 
Rev RNA-binding domain (Malim et al., 1989a). This mutation, which 
affects amino acids 41-44 ef Rev, is located well outside the Rev 
activation domain (Figure 1). However, inclusion of this mutation mark- 
edly increases the yield of full-length Rev protein upon expression in 
E. coil (data not shown). Bacterially expressed GST, GST-Rev, and 
GST-M10 proteins were purified as previously described (Malim et 
al., 1991). Equivalent levels were then coupled to cyanogen bromide- 
activated agarose beads (Pierce) and used to prepare columns with 
a 0.5 ml bed volume. A DNA fragment encoding the Rab ORF (amino 
acids 1-562; Ncoi-Xhol) was cloned into the pGEM3ZF(+) expression 
plasmid, and 35S-labeled Rab protein was prepared in a 200 ~1 rabbit 
reticulocyte lysate-coupied transcription-translation reaction (Pro- 
mega) using T7 RNA potymerase and [35S]methionine/[3~S]cysteine. 
The lysate was then diluted 1:5 with chromatography buffer (CB) (10 
mM HEPES [pH 7.5], 0.1 M NaCI, 1 mM EDTA, 1 mM DTT, 10% 
glycerol, 2 mg/ml BSA, 0.5% NP-40, and 0.25 mM PMSF), and equal 
amounts were loaded onto the immobilized GST, GST-Rev, and GST- 
M10 affinity columns. These were then washed with 10 column vol- 
umes of CB before bound proteins were eluted with 4 column volumes 
of 0.1 M glycine (pH 2.8). Eluted proteins were concentrated and dia- 
lyzed against CB prior to analysis by 12% SDS-PAGE. 
Mammalian Two-Hybrid Assay 
All mammalian expression plasmids were constructed in the context 
of plasmid pBC12-CMV (Matim et al., 1991) with the exception of the 
pG5B-CAT indicator construct, which has been described previously 
(Bogerd and Greene, 1993). pBC12-GAL4-Rab expresses the GAL4 
DNA-binding domain (amino acids 1-147) linked to the full-length rab 
cDNA sequence, pRev-VP16 and pRex-VP16 have been described 
previously (Bogerd and Greene, 1993) and express full-length HIV-1 
Rev and HTLV-I Rex linked to the VP16 transcription activation do- 
main. Variants of Rev (M10 and M32) and Rex (AAD) bearing defective 
activation domains were substituted into this same expression plasmid 
by excision of the wild-type rev gene by cleavage with Sacl and Bglll 
and replacement with a PCR-generated SacI-Bcll DNA fragment en- 
coding the appropriate Rev or Rex mutants. Similarly, PCR-generated 
Saci-Bcll DNA fragments encoding wild-type and mutant (AAD) forms 
of VMV Rev and EIAV Rev were also substituted in place of HIV-1 
Rev to generate the relevant VP 16 fusion protein expression plasmids. 
All Rev and Rex activation domain mutants have been previously de- 
scribed and characterized (Hope et al., 1991 ; Malim et al., 1991 ; Tiley 
et al., 1991; Fridell et al., 1993). The introduced mutations are the 
following: HIV Rev M10, LG(78-79) to DL; HIV Rev M32, L78, L81, 
and L83 all to A; RexAAD, LSLD(90-93) to GGGG; VMV RevAAD, 
LE(114-115) to DL; EIAV RevAAD, L49 and 154 to A. 
COS cell cultures (100 mm) were transfected with 1 I~g of pG5B- 
CAT, 500 ng of pBC12-GAL4-Rab, 5 I~g of a VP16 fusion protein ex- 
pression plasmid, and 500 ng of the internal control indicator plasmid 
pBC12-CMV-13gal using the DEAE-dextran procedure. The parental 
pBC12-CMV expression plasmid served as a negative control. At - 48 
hr posttransfection, cell extracts were prepared and CAT and I~-gal 
expression quantified (Fridell et al., 1995). 
Mammalian Monohybrid Assay 
The pSLIIB indicator construct and plasmids expressing wild-type 
(pcRev) and mutant (pM10 and pM32) forms of Rev have been de- 
scribed previously (Malim et al., 1991 ; Tiley et al., 1992a). The pcTat- 
Rab plasmid expresses a fusion protein consisting of the full-length 
Tat protein linked to the first amino acid of the Rab ORF indicated in 
Figure 3. HeLa cultures (35 mm) were transfected with 1 t~g of the 
pSLIIB-CAT reporter plasmid, 0.5 I~g each of the Tat-Rab fusion pro- 
tein and Rev protein expression plasmid, and 1 llg of carrier DNA 
using the calcium phosphate procedure. The parental pBC12-CMV 
expression plasmid was used as a negative control. Cultures were 
harvested at -48  hr after transfection and CAT activity quantified 
(Fridell et al., 1995). 
HIV-1 Virus Rescue 
HIV-1 provirus rescue assays were performed in COS cell cultures 
essentially as described by Malim et al. (1991). The Rev- provirus 
expression plasmid pHIVARev and the pcRev, pcRex, pBC12-CMV- 
SEAP, pBC12-CMV-CAT, and pBC12-CMV-~3gal expression ptasmids 
have been described previously (Rimsky et at., 1988; Malim et al., 
1991). The Rab expression plasmid pBC12-CMV-Rab contains the 562 
amino acid Rab ORF indicated in Figure 3 (NcoI-Xhol) cloned into 
the expression plasmid pBC12-CMV. Transfections were performed 
as described in Figure 7. Secreted p24 levels were quantified using 
a commercial ELISA kit (DuPont), while SEAP activity was determined 
as described previously (Berger et al., 1988). 
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